Aurion Biotech Doses First Patients in ASTRA Phase 3 Study, Evaluating AURN001 in Patients with Corneal Edema Secondary to Corneal Endothelial Dysfunction

AI Briefing

• – Aurion Biotech announces first patient dosing in ASTRA Phase 3 study of AURN001 for corneal edema, a regenerative cell therapy aimed at restoring vision.
• – AURN001, a single-administration treatment, is being evaluated in patients with corneal endothelial dysfunction.
• – Aurion Biotech is a commercial-stage regenerative cell therapy company focused on eliminating blindness.